4542-46-5

Basic information

• Product Name: morpholin-4-ylethylthiol
• Synonyms: morpholin-4-ylethylthiol;2-(4-Morpholinyl)ethanethiol;2-Morpholinoethanethiol;4-Morpholineethanethiol
• CAS NO: 4542-46-5
• Molecular Formula: C₆H₁₃NOS
• Molecular Weight: 147.23852
• EINECS: 224-893-3
• Mol File: 4542-46-5.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 110.5°C
• Flash Point: 87.3°C
• Appearance: /
• Density: 1.017 (estimate)
• Vapor Pressure: 0.097mmHg at 25°C
• Refractive Index: 1.5500 (estimate)
• CAS DataBase Reference: morpholin-4-ylethylthiol(CAS DataBase Reference)
• NIST Chemistry Reference: morpholin-4-ylethylthiol(4542-46-5)
• EPA Substance Registry System: morpholin-4-ylethylthiol(4542-46-5)

Safety Data

• Hazardous Substances Data: 4542-46-5(Hazardous Substances Data)

Usage

General Description

Morpholin-4-ylethylthiol is a chemical compound with the molecular formula C6H13NOS. It is a thiol compound that contains a morpholine ring and an ethyl group attached to the sulfur atom. This chemical is commonly used in organic synthesis as a building block for the preparation of various organic compounds. It has been found to have an important role in the development of pharmaceuticals and agrochemicals, as well as in the production of various industrial chemicals. Additionally, morpholin-4-ylethylthiol has been studied for its potential use in material science and as a reagent in chemical reactions. Its unique structure and properties make it a versatile compound with various applications in different fields of chemistry.

InChI:InChI=1/C6H13NOS/c1-2-9-7-3-5-8-6-4-7/h2-6H2,1H3

Upstream product

• 420-12-2 thirane 
• 110-91-8 morpholine 
• 3240-94-6 N-(2-chlorethyl)morpholine 
• 3647-69-6 4-(2-chloroethyl)morpholine hydrochride 
• 17356-08-0 thiourea 
• 70020-58-5 4,4'-[dithiobis(ethane-2,1-diyl)]dimorpholine 

Downstream Products

• 16830-82-3 4-ethoxy-thiobenzoic acid S-(2-morpholino-ethyl ester); hydrochloride 
• 611-71-2 MANDELIC ACID 
• 100609-55-0 thiobenzoic acid S-(2-morpholino-ethyl ester); hydrochloride 
• 1229649-34-6 N-(4-((4-(3-(3-tert-butyl-1-p-tolyl-1H-pyrazol-5-yl)ureido)naphthalen-1-yloxy)methyl)pyridin-2-yl)-2-(2-morpholinoethylthio)acetamide 
• 1536199-24-2 C₁₅H₂₃NO₃S₄ 
• 70001-76-2 4-(2-morpholin-4-yl-ethylsulfanyl)-1-phenyl-1H-pyrazolo[3,4-d]pyrimidine 
• 859824-27-4 4-nitro-benzoic acid-[2-(2-morpholino-ethylmercapto)-ethylamide] 
• 88873-86-3 1-phenyl-2-(morpholinoethylthiomethyl)propan-1-one 
• 89816-44-4 bis(morpholinoethylthiomethyl)-1-phenylethan-1-one 
• 81374-84-7 Hydroxy-phenyl-thioacetic acid S-(2-morpholin-4-yl-ethyl) ester 
• 70436-97-4 1-butyl-3,5-bis-(2-morpholin-4-yl-ethylsulfanylmethyl)-4-phenyl-piperidine-4-carboxylic acid ethyl ester 
• 60812-88-6 diphenyl-phosphinothioic acid S-(2-morpholin-4-yl-ethyl) ester 

Relevant articles and documents

Novel pyrimido-heterocyclic compound and preparation method and application thereof

The invention discloses a novel pyrimido-heterocyclic compound and a preparation method and application thereof. The structure of the pyrimido-heterocyclic compound disclosed by the invention is as shown in a general formula I, and the definitions of all substituents are described in the specification and claims. The pyrimido-heterocyclic compound disclosed by the invention has much better inhibitory activity and selectivity for double-mutant EGFR kinase than the existing AZD-9291, can be used for preparing anti-tumor drugs, and overcomes the defect of drug tolerance of the first generation ofEGFR inhibitor.

Design, synthesis and biological evaluation of novel podophyllotoxin derivatives bearing 4β-disulfide/trisulfide bond as cytotoxic agents

A novel series of C-4β-disulfide/trisulfide-containing podophyllotoxin derivatives were designed, synthesized, and biologically evaluated for their cytotoxic activities against human cancer cell lines, including KB (Mouth Epidermal Carcinoma Cells) and KB/VCR (Vincristine-resistant Mouth Epidermal Carcinoma Cells). Most of these compounds exhibited promising moderate to good cytotoxic activities. In particular, some of them displayed even superior activities to that of etoposide, especially for KB/VCR cell lines, indicating that introduction of the disulfide/trisulfide moiety would be beneficial for overcoming the multi-drug resistant limitation of etoposide. Moreover, the metabolic evaluation of the most promising compound was further performed to reveal that disulfide bond can be stable in human plasma over 8 hours, indicating good potential of these compounds for in vivo anti-cancer activities.

NOVEL CYCLOSPORIN DERIVATIVES AND USES THEREOF

The present invention relates to a compound of the Formula (I)): or pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same, a method for treating or preventing viral infections, inflammation, dry eye, central nervous disorders, cardiovascular diseases, cancer, obesity, diabetes, muscular dystrophy, and hair loss.